Anfibatide Phase 1 Clinical Trial in Healthy Volunteers
First Assessment of the Glycoprotein Ib-IV-V Complex Antagonist Anfibatide in Healthy Human Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1) Healthy volunteers, aged 18-28 years, male and female were included, age difference less than 10 years;
- 2) Body weight: with body mass index (BMI) between 19-24, difference less than 10kg in the same group, BMI=body weight(kg)/height2;
- 3) Past medical history: no history of heart, liver, kidney, digestive tract, nervous system and metabolic disorder, or ulcer, significant hemorrhage, without the history of drug allergy and postural hypotension;
- 4) Medical examinations: with normal results in overall examinations (including heart rate, blood pressure, auscultation of heart and lung, palpation of liver and spleen, hepatic and renal function, hematology, coagulation function, urine analysis, stool analysis and occult blood test, electrocardiogram);
- 5) Have not received any medications within 2 weeks before the study;
- 6) Willing to participate in the study and give a signed informed consent form after understanding the study procedures and potential adverse reactions of the study product.
Exclusion Criteria:
- 1) History of HBV or HCV infection;
- 2) Addicted to smoking or alcohol;
- 3) Women during pregnancy, lactation or menstrual period;
- 4) Past history of hemoptysis, bloody stool, bleeding spots in the skin and mucous membrane, or hemorrhagic tendency (find themselves prone to bleeding in gums, nose, skin and mucous membrane, or hemoptysis);
- 5) History of active bleeding (such as peptic ulcer, hemorrhoids, active tuberculosis, subacute bacterial endocarditis, etc);
- 6) Blood platelet count less than 150×109;
- 7) Trauma history (e.g., craniocerebral trauma) recently;
- 8) Past history of unexplained syncope or convulsion;
- 9) History of organic or psychogenic disease or the disabled;
- 10) Persons who were unlikely to participate in the study (such as the infirm) in the investigator's opinion;
- 11) Have donated blood or experienced blood collection in other trials within 3 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Single dose gourp 1
Anfibatide injection at the concentration of 0.33μg/60kg in healthy volunteers
|
|
|
Experimental: Single dose group 2
Anfibatide injection at the concentration of 0.66μg/60kg in healthy volunteers
|
|
|
Experimental: Single dose groups 3
Anfibatide injection at the concentration of1.0μg/60kg in healthy volunteers
|
|
|
Experimental: Single dose group 4
Anfibatide injection at the concentration of 1.5μg/60kg in healthy volunteers
|
|
|
Experimental: Single dose group 5
Anfibatide injection at the concentration of 2.0μg/60kg in healthy volunteers
|
|
|
Experimental: Single dose group 6
Anfibatide injection at the concentration of 3.0μg/60kg in healthy volunteers
|
|
|
Experimental: Single dose group 7
Anfibatide injection at the concentration of 4.0μg/60kg in healthy volunteers
|
|
|
Experimental: Single dose group 8
Anfibatide injection at the concentration of 5.0μg/60kg in healthy volunteers
|
|
|
Experimental: Multiple dose group 9
Give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours
|
|
|
Experimental: Multiple dose group 10
Give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.
|
|
|
Experimental: Multiple dose group 11
Give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours
|
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety endpoints
Time Frame: 24 Hours
|
To investigate the number of adverse events in patients with single or multiple intravenous injection/infusion of Antiplatelet
|
24 Hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area Under Curve (AUC)
Time Frame: Predose, 0,1,2,3,4,6,8,12,24,48,72,96 Hours
|
To observe area under curve characteristics of Anfibatide in single or multiple dose groups
|
Predose, 0,1,2,3,4,6,8,12,24,48,72,96 Hours
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LeesPharm_Anfibatide_Phase1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.